3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Non-Small-Cell Lung
150
Squamous Cell Carcinoma of Head and Neck
76
Head and Neck Neoplasms
75
Stomach Neoplasms
52
Lung Neoplasms
52
Esophageal Neoplasms
34
Neoplasms
33
Uterine Cervical Neoplasms
32
Urinary Bladder Neoplasms
32
Carcinoma, Squamous Cell
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Neoplasm Metastasis
26
Small Cell Lung Carcinoma
23
Breast Neoplasms
23
Cholangiocarcinoma
21
Carcinoma
19
Ovarian Neoplasms
14
Adenocarcinoma Of Esophagus
14
Triple Negative Breast Neoplasms
13
Pancreatic Neoplasms
13
Oropharyngeal Neoplasms
13
Mesothelioma, Malignant
13
Adenocarcinoma
13
Biliary Tract Neoplasms
12
Mesothelioma
11
Gallbladder Neoplasms
11
Esophageal Squamous Cell Carcinoma
10
Carcinoma, Transitional Cell
10
Tongue Neoplasms
9
Laryngeal Neoplasms
9
Interventions
Paclitaxel
6
Carboplatin
6
Gemcitabine
3
pembrolizumab
2
Irinotecan
2
Erlotinib Hydrochloride
2
Capecitabine
2
Bevacizumab
2
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
etoposide phosphate
1
erythromycin propionate-N-acetylcysteinate
1
entrectinib
1
cobimetinib
1
belinostat
1
atezolizumab
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alectinib
1
Vemurafenib
1
Surveys and Questionnaires
1
Oxaliplatin
1
HhAntag691
1
Everolimus
1
Etoposide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms, Unknown Primary
×
Cisplatin
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts